News & Updates
Showing Multidisciplinary articles
Showing
Digital intervention plus phentermine-topiramate cuts weight, CVD risk in adults with obesity
Combination treatment with phentermine-topiramate extended release (ER) and a digitally enhanced lifestyle intervention (DELI) results in a significant and sustained weight reduction, as well as a decrease in cardiovascular disease (CVD) risk, in adults with obesity, reports a study.
Digital intervention plus phentermine-topiramate cuts weight, CVD risk in adults with obesity
28 Mar 2026
Avacincaptad pegol slows geographic atrophy progression
Patients with noncentre point-involving geographic atrophy (GA) who receive avacincaptad pegol (ACP) 2 mg every month (EM) or every other month (EOM) show a persistent decrease in GA growth over 2 years relative to sham therapy, with no new safety signals, according to the GATHER2 study.
Avacincaptad pegol slows geographic atrophy progression
27 Mar 2026
2-year data support nerve-sparing technique in prostate cancer surgery
An updated 24-month analysis of the NeuroSAFE PROOF study continues to support robot-assisted radical prostatectomy (RARP) guided by the nerve-sparing NeuroSAFE technique in men with prostate cancer.
2-year data support nerve-sparing technique in prostate cancer surgery
27 Mar 2026
CKM outcomes in HK after reclassifying obesity by the Lancet Commission’s definition
In an observational study of two community-based cohorts in Hong Kong, 6.7 percent of individuals with BMI ≥25 kg/m2 were reclassified as nonobese after applying the Lancet Commission’s definition of obesity. Individuals with clinical obesity had the highest risk of adverse cardiovascular-kidney-metabolic (CKM) outcomes, while those reclassified as nonobese had an intermediate risk.